29 results about "Albendazole" patented technology

The invention discloses an application of ceritinib in preparation of a medicine for treating echinococcosis. The ceritinib also comprises a pharmaceutically acceptable salt or a hydrate of the salt, and a pharmaceutical composition containing pharmaceutically acceptable auxiliary materials. The invention accidentally discovers that the ceritinib has a remarkable effect of killing protoscolex in vitro. Experimental results show that when the action concentration of albendazole is 80 [mu] M, the fatality rate of albendazole to protoscolex is only 2.5% + / -0.5%, while when the action concentration of ceritinib is 10 [mu] M, the fatality rate of ceritinib to protoscolex can reach 16.00% + / -2.75%, and when the action concentration of ceritinib is 25-80 [mu] M, the fatality rate of ceritinib to protoscolex can reach 100%; microscopic experiments show that when the acting concentration of the ceritinib is 60 mu M, the protoscolex can be completely killed within 8 hours. Therefore, compared with albendazole for clinically assisting in treating the echinococcosis, the ceritinib has the advantages that the effect of killing protoscolex in vitro is more remarkable, the dosage is smaller, the safety is higher, the effect is quicker, and a new drug choice is provided for treating the echinococcosis.

The invention provides an agent for preventing and treating peanut bacterial wilt and a preparation method and application thereof, and belongs to the technical field of pesticide preparations, and the agent is a composite agent formed by scientifically compounding albendazole, carbendazim, kasugamycin, chlorobromoisocyanuric acid, chitosan oligosaccharide, amino-oligosaccharin, a seaweed extract, humic acid, palygorskite and trace elements. According to the invention, efficient inhibition of ralstonia solanacearum is realized, peanut system resistance is obviously activated, root development is promoted, rhizosphere microenvironment is improved, slow release of active components is realized by means of palygorskite, and the pesticide effect period is prolonged. Field trials show that the prevention and control effect reaches 84% or above, the yield increasing rate exceeds 22%, and the composition is environmentally friendly and high in safety. The bactericidal composition can be prepared into a water suspending agent or a dispersible liquid, is suitable for various application modes such as root irrigation and spraying, has the advantages of long lasting period and low resistance risk, and is suitable for large-scale popularization in green agriculture.

The invention discloses an albendazole-ivermectin compound nanoemulsion and a preparation method of the albendazole-ivermectin compound nanoemulsion. The albendazole-ivermectin nanoemulsion is prepared from albendazole, ivermectin, an oil phase, a surfactant, a cosurfactant and a water phase. The preparation method comprises the following steps: dissolving the medicines in a solvent, extracting to obtain an oil phase, removing the solvent, adding the oil phase into a water phase consisting of the surfactant, the cosurfactant and water under stirring, and spontaneously forming the nano-emulsion through low-energy emulsification. The prepared nanoemulsion is small in particle size and good in stability, the solubility and the drug loading capacity of two insoluble drugs can be remarkably improved, the synergistic parasite expelling effect is achieved, and the cure rate is increased. The preparation process is simple, mild in condition and suitable for industrial production.

The present application belongs to the technical field of veterinary medicine, and relates to a kind of veterinary albendazole tablets, and the preparation method of the preparation is provided.The tablet is composed of albendazole, trehalose, sodium taurocholate and other pharmaceutically acceptable binders, disintegrants and lubricants.By spray drying the mixed solution of albendazole, trehalose and sodium taurocholate, the albendazole is fully dispersed, and the amount of trehalose and sodium taurocholate is controlled, which improves the dissolution and stability of the product.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an albendazole dispersing agent and a preparation method thereof. The preparation method comprises the following steps: uniformly mixing and dispersing a modified phospholipid compound, a membrane regulator, albendazole and absolute ethyl alcohol, and performing rotary evaporation to obtain the lipid membrane, and adding normal saline into the lipid membrane, mixing and hydrating to obtain the albendazole dispersing agent. Through the technical means of the invention, the albendazole dispersing agent not only has good encapsulation efficiency and storage stability, but also has good in-vitro release performance, and the drug effect can be quickly exerted.

The invention provides a metal organic framework-albendazole drug delivery system, the drug delivery system comprises a metal organic framework and albendazole, the albendazole (ABZ) is loaded in a metal organic framework (MOF) to form an ABZ-MOF nano material, and the MOF comprises UiO-66-NH2, MIL-125-NH2 or SU-101. The invention also provides a preparation method of the metal organic framework-albendazole drug delivery system. According to the drug delivery system, albendazole is loaded in the metal organic framework, the solubility of albendazole is improved, the bioavailability of albendazole is improved, MOF loaded albendazole of various different metal ions is synthesized, and universality is achieved.

The invention discloses a quantitative analysis method for the content of crystal forms in an albendazole preparation. Specifically, the invention provides a quantitative analysis method for the crystal form content in an albendazole preparation, which comprises the following steps: (1) collecting a near infrared spectrogram of an ABZ preparation sample; (2) establishing a quantitative analysis model; and (3) quantitative analysis of the ABZ crystal form in the ABZ preparation. According to the quantitative analysis method for the crystal form content in the albendazole preparation, the crystal form content in the albendazole preparation is rapidly and quantitatively analyzed on the basis of a PLS multivariate linear correction method and a near infrared spectrum, the crystal form content in the albendazole preparation can be rapidly and efficiently detected without being limited by regions and being detected by high-tech operators, and the medicine quality is controlled.

The invention discloses a targeted B cell epitope peptide monoclonal antibody as well as a preparation method and application thereof, five B cell epitope peptide positive hybridoma cell strains: 2G6H3, 6F11B7, 6F11E4, 4H9D8 and 4H9B7 are successfully screened by utilizing a hybridoma cell technology, and the monoclonal antibody is purified. The five monoclonal antibodies can recognize B cell epitope peptide, rEm.P29 and P29 protein in natural antigen, and 6F11B7, 6F11E4 and 2G6H3 which are high in specificity and affinity are selected for evaluating the curative effect of an abdominal cavity infected animal model. The results show that the monoclonal antibody can significantly inhibit the growth of echinococcus multilocularis in mice, has a curative effect higher than that of a clinical drug albendazole, does not have side effects such as liver and kidney function impairment caused by chemotherapeutic drugs, and does not affect other organs. The invention has treatment potential and treatment safety, and provides a brand new treatment strategy for clinically treating the alveolar echinococcosis.

This invention discloses a method for preparing albendazole, belonging to the field of pharmaceutical preparation technology. The method includes: (1) cyclization reaction: using methyl cyanocarbamate and 4-(propylthio)phenyl-1,2-diamine or their hydrochloride as raw materials, reacting in water, methanol, ethanol or a mixed solvent in the presence of an acidic catalyst or an alkaline buffer; (2) crystallization and separation of crude product: adjusting the pH of the reaction solution to 3-5, and separating the solid and liquid to obtain the crude product; (3) washing and purification: the crude product is washed successively with toluene, methanol and water, and dried to obtain the purified product; (4) refining and post-treatment: dissolving, decolorizing and recrystallizing with a formic acid-water mixed solvent, drying, pulverizing and sieving, and packaging to obtain the finished product. This invention uses a green and environmentally friendly solvent system, suppresses side reactions through precise pH control, optimizes the three-stage washing and recrystallization process, achieves a molar yield of over 88%, a purity of 99.85%, meets pharmaceutical standards, and is suitable for large-scale production.

The present invention discloses the use of the fatty acid amide hydrolase inhibitor PF-3845 as a drug for the preparation of a drug for treating alveolar echinococcosis. The present invention finds that the fatty acid amide hydrolase inhibitor PF-3845 can destroy the head hook, sucker, microvilli and other structures of the protoscolecus of Echinococcus multilocularis, causing the protoscolecus to lyse and die, and can also destroy the structure of the vesicles in the tapeworm stage, causing the vesicles to collapse. This shows that the fatty acid amide hydrolase inhibitor PF-3845 has a good killing effect on Echinococcus multilocularis and can be used as an alternative to albendazole to treat echinococcosis, with good application prospects.

This invention relates to the field of veterinary drugs, specifically to an albendazole-ivermectin premix and its preparation method. The premix, by weight percentage (100%), comprises the following raw materials: albendazole 9.5-10.5%, ivermectin microcapsules 0.19-0.21%, sodium chloride 12-24%, and the balance being modified starch. The albendazole-ivermectin premix prepared by this invention can be uniformly mixed through a simple process, exhibiting high homogeneity.

The application belongs to the technical field of tumor treatment, and discloses a method for enhancing the anti-tumor effect of an oncolytic virus M1, and specifically discloses application of albendazole in preparation of a product for enhancing the anti-tumor effect of the oncolytic virus M1. The application first proposes that ABZ can increase the therapeutic effect of OVM1 in treating tumors, and has small toxicity and low price. It is proved through experiments that OVM1 combined with ABZ treatment can significantly promote the activity inhibition of tumors in vitro, and the anti-tumor effect of the combined treatment on immune-competent mice is far greater than that on immune-deficient mice; further detection finds that this process depends on CD8 + T cells play a synergistic anti-tumor effect. At the same time, ABZ and OVM1 combined with CTLA4 antibody can not only further enhance the anti-tumor effect, but also overcome the drug resistance of ICB treatment based on CTLA4. The application provides a new strategy for synergistic oncolytic virus treatment and overcoming ICB drug resistance.

The utility model discloses a mixer for mixing albendazole ivermectin premix, which comprises a machine body, a hopper and a valve device, the hopper is arranged at the lower end of the machine body, fixedly connected with the machine body and communicated with the machine body, and the valve device is arranged at the upper end of the hopper and fixedly connected with the hopper. The machine body, the hopper, the valve device, the auxiliary device, the slapping assembly, the rotating seat, the slapping plate, the tension spring, the linkage assembly, the supporting seat, the rotating rod, the extrusion wheel, the control assembly, the supporting plate, the motor, the first belt wheel, the second belt wheel and the rubber block are used in cooperation. The problems that in the prior art, a part of premixing agent is left and attached to the inner wall of the hopper and cannot be well treated, so that discharging of the hopper is not thorough, and the part of premixing agent is wasted are solved.

The invention provides a parasite expelling composition and application thereof in yak breeding, the parasite expelling composition comprises albendazole and myrobalan acid, through the synergistic effect of albendazole and myrobalan acid, on one hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes, prolongs the half-life period of albendazole, improves the bioavailability and optimizes the pharmacokinetic process, on the other hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes, and on the other hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes; on the other hand, the two act on parasite tubulin synthesis and a body surface biofilm structure respectively to form double-target synergistic killing, so that the parasite expelling effect is remarkably improved; chebulinic acid can repair gastrointestinal mucosa, regulate flora balance, enhance appetite and effectively counteract irritant injury of albendazole to gastrointestinal tracts; the parasite expelling rate reaches 95% or above, the average daily gain reaches 369 g / d, and no obvious influence is caused to the blood system and liver and kidney functions of yaks; the composition has the characteristics of simple formula, gastrointestinal protection and convenience in administration, is adaptive to the current breeding situation of high parasite infection rate of yaks in plateau pasturing areas, and has a good industrial application prospect.

The invention relates to the technical field of biological manufacturing of veterinary bulk drugs, and discloses an immobilized enzyme catalyst-based albendazole side chain oriented synthesis process, which comprises a magnetic core; the proton channel array functional layer is coated on the substrate and is made of a metal organic framework material; the flexible molecular arm is connected to the outer surface of the functional layer; and a primary catalytic enzyme and a coenzyme regenerating enzyme covalently bonded by a flexible molecular arm. In a reaction medium, the catalyst, a substrate 5-(propylthio)-1H-benzo [d] imidazole-2-amine, glucose and a coenzyme NADP < + > are subjected to a catalytic reaction under mild conditions. The pH value of a double-enzyme catalysis microenvironment is stabilized through a proton channel constructed by a ZIF-8 layer, the activity loss in the enzyme immobilization process is reduced through the design of a flexible molecular arm, and the catalyst is conveniently recycled through a magnetic core. The process has the advantages of mild reaction conditions, high product selectivity, good catalyst operation stability and repeated use.

The application discloses albendazole and ivermectin premix and a preparation method thereof. The premix comprises albendazole 8-15%, ivermectin 0.2-0.4%, double-layer inclusion carrier 20-30% and various auxiliary materials in percentage by mass. The application adopts the double-layer inclusion carrier formed by inner layer hydroxypropyl-beta-cyclodextrin and outer layer hydroxypropyl methylcellulose phthalate and povidone K30 to form an enteric barrier. The preparation method comprises the steps of inner layer inclusion, outer layer dispersion, mixing and granulation. The relative bioavailability of the premix reaches 203%-221%, the pig ascarid drive rate is 98.7%-99.5%, the scabies mite negative conversion rate is 98%-100%, the diarrhea incidence is only 2%-3%, the premix is safe for pregnant sow groups, and no adverse reactions such as abortion, premature birth and loss of appetite occur in all test pigs during the test period. The problems of uneven mixing, low bioavailability and large side effects of traditional preparations are solved, and the premix is suitable for livestock and poultry parasite prevention and treatment.

To provide control methods by orally administered drugs for Platyhelminthes, Polyopisthocotylea, Heteraxine heterocerca.SOLUTION: Provided is a pesticide for Platyhelminthes, Monogenea, Polyopisthocotylea, Heteraxine heterocerca that infested fish, containing benzimidazole compounds as active ingredients. Preferably, benzimidazole compounds are one or more compounds selected from albendazole, febantel, fenbendazole, oxfendazole, mebendazole, flubendazole, oxibendazole, triclabendazole, licobendazole, and thiabendazole.SELECTED DRAWING: None

This invention relates to the field of veterinary drug technology, and proposes a compound composition for the prevention and treatment of shrimp hepatocellular carcinoma and its preparation method. The compound composition comprises the following raw materials: albendazole, ivermectin, and glycyrrhizic acid monoammonium salt. The components in the compound composition for the prevention and treatment of shrimp hepatocellular carcinoma provided by this invention work synergistically to safely control the disease and ensure the healthy and sustainable development of aquaculture.

The present invention relates to the field of treatment of parasites, in particular to a method of treating subjects suffering from soil transmitted helminths by administering a pharmaceutical composition comprising ivermectin and a benzimidazole carbamate formulated as a fixed-dose combination, a pharmaceutical composition in the form of a fixed-dose combination comprising ivermectin and benzimidazole carbamate, said composition for use in the treatment of subjects suffering from parasites and a method for producing a fixed-dose combination comprising ivermectin and benzimidazole carbamate.

The invention relates to the field of medicine crystal forms, in particular to an albendazole-acesulfame potassium salt crystal form A, a preparation method and application. The molar ratio of the albendazole anion to the acesulfame cation in the salt structure is 1: 1. The crystal form A of the albendazole-acesulfame potassium salt prepared by the preparation method disclosed by the invention has relatively good dissolving property and relatively good flowability. Meanwhile, the preparation method is simple, good in reproducibility, low in cost and environment-friendly.

The invention discloses a method for detecting the crystal form content of albendazole. According to the method, an infrared paste method is adopted, an albendazole sample to be detected, an albendazole crystal form I reference substance and an albendazole crystal form II reference substance are uniformly mixed into paste in an agate mortar by using liquid paraffin, the sample paste is filled into a liquid pool, the liquid paraffin is used for preparing a blank, an infrared spectrometer is used for collecting an instrument background, and the liquid paraffin is used for detecting the albendazole crystal form I reference substance and the albendazole crystal form II reference substance. And then carrying out absorbance collection on the sample and the reference substance. The method has the advantages of simplicity and convenience in operation, high analysis speed, high sensitivity, good repeatability, accurate and reliable data and the like.

The invention discloses a surface-modified screen-printed electrode, a preparation method and application of the surface-modified screen-printed electrode in albendazole detection, and belongs to the technical field of electrochemical sensing. The method comprises the following steps: firstly, dropwise adding a hydrogen peroxide solution to the surface of a working electrode of a screen-printed electrode for modification treatment to obtain a modified working electrode; washing the surface of the modified working electrode with ultrapure water and drying; and finally, dispensing the multi-walled carbon nanotube dispersion liquid on the surface of the modified working electrode, and drying to obtain the surface-modified screen-printed electrode. Mild pretreatment is carried out through the hydrogen peroxide solution with the specific mass fraction (5-30%), the surface contact angle of the screen-printed electrode can be remarkably reduced, and the screen-printed electrode becomes hydrophilic from hydrophobic; an ideal interface is created for uniform loading of a multiwalled carbon nanotube aqueous nano material dispersion liquid, and the core problem that a modification layer is easy to agglomerate and fall off is solved; the pretreatment thought provides a universal interface solution for construction of various electrochemical sensing platforms based on screen-printed electrodes.

The utility model relates to the technical field of medicine purification, and discloses a purification device of veterinary anthelmintic albendazole, which comprises a box body, the outer surface of the lower end of the box body is fixedly connected with supporting legs, the outer surface of the upper end of the box body is fixedly connected with a working tank, the inner surface of the upper end of the working tank is fixedly connected with a crusher, and the crusher is fixedly connected with a water pump. The outer surface of the upper end of the box body is provided with an extraction tank, the outer surface of the front end of the box body is provided with a wastewater collection pool, the outer surface of the front end of the box body is fixedly connected with an air cylinder, the inner surface of one side of a working tank is fixedly connected with a supporting rod, and the outer surface of one side of the supporting rod is fixedly connected with a dissolving tank. According to the crystal drying device, residues attached to the surface of a filter screen can be cleaned through the arranged filter assembly, the maintenance time is saved, crystals are dried for three times through the arranged drying assembly, the working efficiency of the device is improved, and a better use prospect can be brought.

The invention discloses an application of amlodipine in preparation of a medicine for treating echinococcosis. The amlodipine further comprises a pharmaceutically acceptable salt of the amlodipine and a pharmaceutical composition containing pharmaceutically acceptable auxiliary materials. An echinococcosis killing experiment result shows that when the highest action concentration of albendazole in an experiment is 80 [mu] M, the fatality rate of albendazole to protoscolex is only 2.5% + / -0.5%, when the action concentration of amlodipine is 20 [mu] M, the fatality rate of albendazole to protoscolex can reach 2.5% + / -0.5%, and when the action concentration of amlodipine is 60-80 [mu] M, the fatality rate of albendazole to protoscolex can reach 100%; microscopic experiments show that when the action concentration of amlodipine is 60 [mu] M, protoscolex can be killed only in 8 hours. Therefore, compared with albendazole for clinical adjuvant treatment of the echinococcosis, the amlodipine disclosed by the invention has the advantages of more obvious effect of killing protoscolex in vitro, less dosage, higher safety and quicker action, and has important reference value for developing a new drug for treating the echinococcosis.

The invention relates to the technical field of albendazole treatment, and particularly discloses a pharmaceutical composition for treating albendazole, 2-8 parts of nefenavir, 30-50 parts of polylactic acid-glycolic acid copolymer (PLGA), 5-15 parts of chitosan, 3-8 parts of sodium cholate and 1-3 parts of vitamin E succinate. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 5-15 parts of albendazole, 2-8 parts of nefenavir, 30-50 parts of polylactic acid-glycolic acid copolymer (PLGA), 5-15 parts of chitosan, 3-8 parts of sodium cholate and 1-3 parts of vitamin E succinate. 20 to 35 parts of lactose and 0.5 to 2 parts of magnesium stearate. The albendazole can inhibit synthesis of polypide microtubulin, the nefenavir is an anti-HIV protease inhibitor and can assist the albendazole to penetrate through the cyst wall of echinococcal, penetrability is enhanced through drug combination, the problem that the albendazole is limited in curative effect and depends on host immunity is solved, the albendazole and sodium cholate form a eutectic crystal, and the albendazole-sodium cholate co-crystal is used for preparing the albendazole-sodium cholate co-crystal. The dissolution behavior is effectively improved; in addition, as an antioxidant, vitamin E succinate can reduce oxidative degradation of albendazole in an acid environment, and the vitamin E succinate and the PLGA-chitosan slow release system cooperate to guarantee the drug stability.

This invention relates to the field of pharmaceutical premixes, addressing the problem in existing technologies of simultaneously ensuring uniform dispersion of the active pharmaceutical ingredient during preparation and when the premix is ​​used with drinking water. It provides an albendazole-ivermectin premix and its preparation method, comprising the following steps: S100, dissolving ivermectin in ethanol to obtain a first solution; adding albendazole and water to the first solution to obtain a first suspension; S200, adding an adjuvant to the first suspension to obtain a second suspension; S300, mixing the second suspension with a soluble carrier, and then granulating to obtain the albendazole-ivermectin premix. This invention, by dissolving ivermectin in a mixed solvent of ethanol and water, ensures the uniformity of ivermectin in the solution system. Furthermore, when mixing the solution with a soluble carrier, it significantly improves the uniformity of ivermectin within the carrier, allowing for more precise dosage of ivermectin when using the albendazole-ivermectin premix.

The invention relates to the technical field of pharmaceutical compositions, in particular to an albendazole suspension preparation and a preparation method thereof.The albendazole suspension preparation is obtained by mixing an albendazole inclusion compound, propylene glycol, a thickener, an emulsifier, a preservative, a stabilizer, a suspending aid, an antioxidant, deionized water and an acidity regulator, the albendazole clathrate compound is prepared from albendazole, chitosan and hydroxypropyl-beta-cyclodextrin, the hydroxypropyl-beta-cyclodextrin has a hydrophilic outer surface and a lipophilic central cavity, and the hydrophobic interaction of the hydroxypropyl-beta-cyclodextrin can accommodate a lipophilic drug albendazole, so that the solubility and the stability of the albendazole can be effectively improved, and the albendazole clathrate compound can be used for preparing a medicine for treating the albendazole. The albendazole clathrate compound has the advantages that the albendazole clathrate compound is prepared from hydroxypropyl-beta-cyclodextrin and chitosan, the chitosan has mucous membrane adhesion, the stagnation time of the albendazole clathrate compound on gastrointestinal mucosa is prolonged by grafting the chitosan to the surface of the hydroxypropyl-beta-cyclodextrin, the absorbability and bioavailability of gastrointestinal tracts are further improved, the albendazole clathrate compound and the hydroxypropyl-beta-cyclodextrin have a synergistic effect, the drug effect of the albendazole is improved, and the albendazole clathrate compound has a wide application prospect.

The application discloses a kind of high bioavailability albendazole nanocrystals and preparation method thereof.The nanocrystals of the application are prepared by mixing albendazole, natural source glycoside stabilizer and water to form a suspension, and then using wet medium grinding.The average particle size is 100-500nm.The nanocrystals are obtained by dispersing albendazole in natural source glycoside solution and then nano-treating, with high drug loading, which can greatly improve the solubility and dissolution of albendazole, and then improve its absorption and bioavailability.The stabilizer used in the application is abundant in resources, natural and economical, and the preparation process is simple, efficient and safe, which is suitable for industrial production, and provides a high bioavailability intermediate for albendazole preparation.